University of Cologne | MedPath Search

Found 407 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "University of Cologne"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

App Based Study on the Symptoms of Patients With Allergic Rhinitis in the Pollen Season

Completed

Conditions: Allergic Rhinitis

First Posted Date: 2017-04-13

Last Posted Date: 2017-10-25

Lead Sponsor: University Hospital of Cologne

Target Recruit Count: 173

Registration Number: NCT03112252

Locations: 🇩🇪
Institute of Medical Statistics, Informatics and Epidemiology, Cologne, NRW, Germany

Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: ORALVAC COMPACT BÄUME

First Posted Date: 2017-03-31

Last Posted Date: 2017-10-25

Lead Sponsor: University Hospital of Cologne

Target Recruit Count: 164

Registration Number: NCT03097432

Locations: 🇩🇪
UHCologne, Cologne, Germany

TIII Over TI in Subjects With Myocardial Infarction

Completed

Conditions: NSTEMI - Non-ST Segment Elevation MI

Interventions: Other: Non interventional study

First Posted Date: 2017-02-17

Last Posted Date: 2017-02-17

Lead Sponsor: University of Cologne

Target Recruit Count: 903

Registration Number: NCT03057093

Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Drug: Cycles N8, N5 and N6
Drug: Cycles N5 and N6

First Posted Date: 2017-02-03

Last Posted Date: 2017-02-06

Lead Sponsor: University of Cologne

Target Recruit Count: 360

Registration Number: NCT03042429

Locations: 🇩🇪
University of Cologne, Koln, Germany

Effects Of An 8-Weeks Mindfulness-based Intervention In Individuals With Subjective Cognitive Decline

Not Applicable

Completed

Conditions: Cognitive Dysfunction

Interventions: Behavioral: Health education weekly courses for 8 weeks
Behavioral: Mindfulness weekly courses for 8 weeks

First Posted Date: 2016-12-29

Last Posted Date: 2025-02-20

Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Target Recruit Count: 168

Registration Number: NCT03005652

Locations: 🇪🇸
The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
🇫🇷
The Clinical Research Memory Centre of Lyon (CMRR), department of the University Hospitals of Lyon - Hospices Civils de Lyon (HCL), Lyon, France
🇩🇪
The Department of Psychiatry at University of Cologne (UKK), Cologne, Germany

and more 1 locations

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Nivolumab
Drug: Adriamycin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2016-12-29

Last Posted Date: 2025-04-03

Lead Sponsor: University of Cologne

Target Recruit Count: 110

Registration Number: NCT03004833

Locations: 🇩🇪
University Hospital of Cologne, Cologne, Germany

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

Phase 1

Withdrawn

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: JCAR015

First Posted Date: 2016-11-25

Last Posted Date: 2017-04-10

Lead Sponsor: Celgene

Registration Number: NCT02973191

Locations: 🇮🇹
Azienda Ospedaliera Citta della Salute e della Scienza di Torino, Torino, Italy
🇪🇸
ICO-Hospital Germans Trias i Pujol, Barcelona, Spain
🇩🇪
Universitaetsklinikum Ulm, Ulm, Germany

and more 15 locations

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

Phase 3

Terminated

Conditions: Dry Eye Syndromes

Interventions: Drug: AGN-195263
Drug: Vehicle

First Posted Date: 2016-11-17

Last Posted Date: 2018-11-30

Lead Sponsor: Allergan

Target Recruit Count: 43

Registration Number: NCT02965846

Locations: 🇵🇭
The Medical City, Pasig City, Philippines
🇮🇹
Ospedale San Giuseppe, Universita di Milano, Milano, Italy
🇩🇪
Ludwig-Maximilians-University, Dept of Ophthalmology, Munich, Germany

and more 46 locations

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Biological: Obinutuzumab
Drug: Cyclophosphamide
Drug: Venetoclax
Biological: Rituximab
Drug: Ibrutinib
Drug: Bendamustine

First Posted Date: 2016-10-31

Last Posted Date: 2024-12-30

Lead Sponsor: German CLL Study Group

Target Recruit Count: 926

Registration Number: NCT02950051

Locations: 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱
Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱
Antonius Ziekenhuis Sneek, Sneek, Netherlands

and more 158 locations

Enhancing Recovery in Early Schizophrenia

Phase 2

Recruiting

Conditions: Schizophrenia

Interventions: Drug: Cannabidiol as add-on
Drug: Placebo as add-on

First Posted Date: 2016-10-06

Last Posted Date: 2024-12-27

Lead Sponsor: Central Institute of Mental Health, Mannheim

Target Recruit Count: 180

Registration Number: NCT02926859

Locations: 🇩🇪
Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, BW, Germany
🇩🇪
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich, Munich, BY, Germany
🇩🇪
Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte, Berlin, B, Germany

and more 3 locations